|
|
|
| Chromosome Karyotypic Analysis of 167 Cases with Chronic Myeloid Leukemia |
| XIN Xiaoli, SU Xiaoli, GAO Shan, et al |
| The First Affiliated Hosptital of Air Force Military Medical University, Shaanxi Xi'an 710032, China |
|
|
|
|
Abstract Objective: To explore the significance of chromosomal karyotype changes at different stages in the diagnosis, treatment, progression and prognosis of chronic myeloid leukemia(CML).Methods: From July 2019 to Deceber 2021, 167 newly diagnosed CML patients were treated in The First Affiliated Hosptital of Air Force Military Medical University. Chromosome preparation was made using 24 hours short-term culture of bone marrow cells, and R-banding technique was used for chromosome karyotype analysis. The genetic characteristics and significance of the disease were observed.And an analysis was conducted of the differences between chromosomal variant translocations and additional chromosomal abnormalities and classical Ph+ CML in the diagnosis and treatment of the disease. Results: In the 167 cases of CML patients, 104 cases was male, 63 cases was female, and the age range was between 11 and 86. By analyzing the karyotype of 167 cases CML pateints, 7 cases (4.2%) were non mitotic, 154 cases were Ph chromosome positive (Ph+) and 6 cases were Ph chromosome negative (Ph-). In the 154 cases of Ph+ pateints, 126 cases were classical Ph+ and 28 cases were variant rearrangements or additional chromosome abnormalities, include +8, +Ph, -Y, der (17), del (3p), del (15q), del (11p), add (21q), add (2q) and so on, the majority were +8, +Ph, -Y, der (17). Conclusion: In the chromosome karyotypic analysis of CML, Ph chromosome was the genetic marker. The complexity of chromosome karyotype is closely related to CML treatment, progress and prognosis. The more complexity of the chromosomes, the worse prognosis of the patient.
|
|
|
|
|
|
[1] V R Minciacchi,R Kumar,D S Krause.“Chronic myeloid leukemia: a model disease of the past,present and future[J].Cells,2021,10(1):117.
[2] M W Deininger,N P Shah,J K Altman,et al.“Chronic myeloid leukemia,version 2.2021,NCCN clinical practice guidelines in oncology[J].Journal of the National Comprehensive Cancer Network,2020,18(10): 1385-1415.
[3] K Allen-Proctor,E Ruckdeschel,R Naous.“A novel three-way philadelphia variant t (9; 22; 17)(q34; q11.2; q12) in chronic myeloid leukemia: a case report[J].Molecular and Clinical Oncology,2018,8(20): 300-301.
[4] H Zhao,Y Chen,C Shen,et al.“Breakpoint mapping of at (9;22; 12) chronic myeloid leukaemia patient with e14a3 BCRABL1 transcript using Nanopore sequencing[J].The Journal of Gene Medicine,2021,23(1):3276.
[5] W Al-Achkar,A Wafa,T Liehr.“A new t (9; 11; 20;22)(q34; p11.2; q11.21; q11) in a philadelphia-positive chronic myeloid leukemia case[J].Oncology Letters,2013,5(2): 605-608.
[6] 沈悌,赵永强.血液病诊断及疗效标准[M].第4版.北京:科学出版社,2018.
[7] McGowan-Jordan J,Simons A,Schmid M.ISCN 2016: an international system for human cytogenomic nomenclature[M].Basel:Karger,2016.41-43.
[8] Costa D,Grau J,Espinet B,et al.Conventional and molecular cytogenetic studies to characterize 32 complex variant philadelphia translocations in patients with chronic myeloid leukemia[J].Oncol Lett,2019,17(6): 5705-5710.
[9] Molica M,Massaro F,Breccia M.Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update[J].Expert Rev Mol Diagn,2017,17(11):1001-1008.
[10] 董晓燕,李玉龙,邬成业,等.伴Ph阳性附加染色体异常慢性髓性白血病的生物学特征及疗效分析[J].中华血液学杂志,2021,42(8):660-665.
[11] Tashfeen S,Mahmood R,Khan SA,et al.Additional chromosomal abnormalities in philadelphia positive chronic myeloid leukemia[J].Pak Med Sci,2020,36(2):208-212.
[12] Radich JP,Deininger M,Abboud CN,et al.Chronic myeloid leukemia,version 1.2019,NCCN clinical practice guidelines in oncology[J].Natl Compr Canc Netw,2018,16(9):1108-1135. |
|
|
|
2022, Vol. 28 
